---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-012932"
form_type: "8-K"
ticker: null
cik: "0001827506"
company_name: "Tourmaline Bio, Inc."
filed_at: "2023-04-14T23:59:59+00:00"
generated_at: "2026-06-17T02:07:33.429256+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Talaris eliminates ~95% of remaining workforce; CEO and three other executives depart

## Summary
- April 2023 reduction of ~80 employees (95% of remaining staff); total severance costs estimated at $8.7M through Q2 2023.
- CEO Scott Requadt, CMO Nancy Krieger, CTO Michael Zdanowski, and CHRO Andrew Farnsworth all leaving company.
- CFO Mary Kay Fenton enters retention agreement; eligible for cash bonus upon strategic transaction or liquidation.
- Prior February reduction cut ~1/3 of workforce; company continues evaluating strategic alternatives.
- Reduction substantially complete by May 26, 2023; WARN Act severance provided.

## SEC filing metadata
- accession: 0000950170-23-012932
- form_type: 8-K
- cik: 0001827506
- company_name: Tourmaline Bio, Inc.
- filed_at: 2023-04-14T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.05, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/tals-20230414.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-012932
- JSON: https://secwatch.observer/filing/0000950170-23-012932.json
- Plain text: https://secwatch.observer/filing/0000950170-23-012932.txt

## Key facts
- Executive change
  Scott Requadt resigned as President and Chief Executive Officer at Tourmaline Bio, Inc..
  - Action: resigned
  - Role: President and Chief Executive Officer
  source text: Scott Requadt, President and Chief Executive Officer, effective May 26, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm
- Executive change
  Andrew Farnsworth resigned as Chief Human Resources Officer at Tourmaline Bio, Inc..
  - Action: resigned
  - Role: Chief Human Resources Officer
  source text: Andrew Farnsworth, Chief Human Resources Officer, effective May 26, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm
- Executive change
  Michael Zdanowski resigned as Chief Technology Officer at Tourmaline Bio, Inc..
  - Action: resigned
  - Role: Chief Technology Officer
  source text: Michael Zdanowski, Chief Technology Officer, effective April 28, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm
- Executive change
  Nancy Krieger resigned as Chief Medical Officer at Tourmaline Bio, Inc..
  - Action: resigned
  - Role: Chief Medical Officer
  source text: Nancy Krieger, Chief Medical Officer, effective April 28, 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm
- Restructurings & Charges
  Tourmaline Bio, Inc. announced a restructuring with charges of approximately $5.8 million (approximately 80 additional employees, or approximately 95% of the Company's remaining workforce).
  - Type: restructuring
  - Charge: approximately $5.8 million
  - Headcount: approximately 80 additional employees, or approximately 95% of the Company's remaining workforce
  source text: the Company estimates it will incur cash-based severance and other employee termination-related costs of approximately $5.8 million in the second quarter of 2023 related to the April Reduction in Force
  evidence_url: https://www.sec.gov/Archives/edgar/data/1827506/000095017023012932/0000950170-23-012932-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.